{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-266688","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2026-06-11T11:12:53+00:00","discovered_at":"2026-06-11T11:15:00.249472+00:00","generated_at":"2026-06-11T11:15:17.200594+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Climb Bio Announces Positive Initial Phase 1b Data for Budoprutug in Immune Thrombocytopenia","bullets":["Phase 1b enrolled 15 patients at 250 mg (n=6) and 500 mg (n=9) doses, median follow-up 38 and 12 weeks respectively.","Budoprutug was well tolerated with no serious adverse events, no discontinuations, and all AEs Grade 1-2.","In 250 mg cohort, B-cells depleted by >90% at Week 4; mean platelet count increased by 111,000/µL at Week 24.","Four of six patients achieved durable platelet responses; two had platelet levels ≥100x10^3/µL for over 24 weeks.","Of four patients previously treated with rituximab, three responded to budoprutug, two with durable/complete responses."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-266688","json":"https://secwatch.observer/filing/0001193125-26-266688.json","markdown":"https://secwatch.observer/filing/0001193125-26-266688.md","text":"https://secwatch.observer/filing/0001193125-26-266688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526266688/0001193125-26-266688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526266688/d63753d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:15:17.200594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}